Compare Ginkgo Bioworks Holdings Inc (DNA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Trip.com Group Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Trip.com Group Ltd trades at $38.9 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 31.1× Ginkgo Bioworks Holdings Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Trip.com Group Ltd for 79 Days on average.
| DNA | TCOM | |
|---|---|---|
Market Cap | $763.64M | $23.75B |
Volume | 3,204,177 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $78.96 |
52-Week Low | $5.48 | $37.96 |
Typical Hold Time | 7 Days | 79 Days |
Enterprise Value | $865.59M | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Trip.com (TCOM) trades at $37.96, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 earnings of $1.07 per share, beating expectations, with revenue reaching $62.41 billion in 2025 and net income margin of 36.9%. Recent regulatory challenges and market volatility have pressured the stock, though analyst consensus remains overwhelmingly positive with a $56.64 price target.
The stock presents a value opportunity with attractive valuation multiples (P/E 7.34, EV/EBITDA 3.43) but faces near-term headwinds from regulatory changes and competitive pressures. Strong cash flow generation and international expansion provide upside potential, though investors should monitor execution risks amid shifting market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
